Thus, excessive activation of TLR4 increases the risk of inflammatory diseases and CRC, and—as occur to TLR2—potential inhibitors of TLR4/NF-κB pathway have also been considered as therapeutic agents in CRC (184). The gene discussed is TLR4; the disease is colorectal carcinoma.